Vivani Medical, Inc. Annual Report: A Year in Review

I’ve put together this guide to help you understand Vivani Medical’s performance. Instead of wading through dense legal filings, I’ve broken down the key takeaways to give you a clear picture of where the company stands.

1. What does this company do?

Vivani is a biotech company developing "set-it-and-forget-it" implants using their "NanoPortal" technology. They aim to solve the problem of patient non-compliance with medication. For popular weight-loss drugs like Wegovy, up to 76% of patients stop their treatment within two years because weekly injections are a burden. Vivani aims to replace these with a tiny implant that delivers medication for six months or longer. Their lead project, NPM-139, uses this platform to deliver semaglutide.

2. Major Wins: The "LIBERATE-1" Milestone

The biggest news this year was the successful completion of LIBERATE-1, their first human trial, which tested the safety of the NanoPortal implant.

• Safety & Success: The study showed the implant was well-tolerated with no serious safety issues, confirming the titanium-based technology is safe for human use.
• Strategic Pivot: Vivani is now prioritizing NPM-139, a six-month weight-loss implant. They are currently scaling up manufacturing and plan to start formal clinical trials in early 2026.
• Preclinical Promise: In animal tests, the implant helped subjects lose about 20% of their body weight over six months while keeping drug levels steady, proving the technology works as intended.

3. Financial Health & Spending

Vivani is in the research phase and does not yet generate revenue from product sales.

• Cash Position: At the end of 2023, the company held approximately $18.4 million in cash. With a market value of roughly $45.9 million as of mid-2025, the company maintains a lean operation.
• The "Burn": The company spent about $22.5 million in 2023 on research, clinical trial preparation, and manufacturing. Management anticipates the need for additional capital to complete upcoming trials, which may involve debt financing or the issuance of additional shares.

4. The "Cortigent" Spin-off

Vivani is working to separate its legacy neurostimulation business, Cortigent, Inc. The goal is to focus entirely on the NanoPortal drug delivery business. This process remains ongoing as the company navigates regulatory reviews and market conditions.

5. Key Risks

• Share Dilution: Because the company relies on selling stock to fund operations, issuing more shares can reduce your ownership percentage and potential future earnings per share.
• Regulatory Hurdles: The company’s value is tied to FDA approval. Later-stage trials are expensive and complex, carrying inherent risks of failure or timeline delays.
• Manufacturing: Vivani must successfully scale the production of tiny, complex medical devices. The company’s commercial viability depends on its ability to manufacture these implants consistently at scale.

Future Outlook

Vivani is playing a long game. They have successfully moved from lab theory to human testing, which is a significant milestone for a biotech firm. To evaluate the company's progress, keep a close eye on their cash runway and the specific timeline for the 2026 clinical trials. These factors will be the primary drivers of the company’s long-term success.

Disclaimer: I am an AI, not a financial advisor. This summary is for educational purposes and should not be taken as investment advice. Always do your own research before buying stocks.